Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals
Frank Vinluan / medcitynews - Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Akt…
AI Summary: Aktis Oncology’s debut on the public market raised $318M, buoyed by a 25% first‐day bounce. The IPO not only generated strong investor enthusiasm for biotech in 2026 but also signals the company’s ambitious plans to extend its portfolio of innovative miniprotein radioconjugates for targeted cancer therapy.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months
Gene‑editing trials explore one‑time fix for high cholesterol / 3 months
Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 3 months
Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months
Tumor bacteria drive head and neck immunotherapy resistance / 4 months
Giredestrant lowers recurrence risk in early-stage breast cancer / 5 months
Protego Bio Secures $130M for AL Amyloidosis Therapy Development / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Trump Administration, Alzheimer's disease, Supply Chain, FDA and look for the RSS link.
StackHealth Time Machine